Arrowhead's Plozasiran Shows Significant Efficacy in Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 28 2026
0mins
Should l Buy ARWR?
Source: Newsfilter
Arrowhead Pharmaceuticals Inc. saw its stock rise by 8.73% as it crossed above the 5-day SMA, reflecting positive investor sentiment.
The catalyst for this movement is the announcement of significant efficacy results from a two-year study on plozasiran, which demonstrated an 83% median reduction in triglyceride levels among patients with severe hypertriglyceridemia. The drug's safety profile remained consistent, with no acute pancreatitis events reported, bolstering confidence in its therapeutic potential. Arrowhead plans to complete Phase 3 studies and submit a supplemental New Drug Application to the FDA by the end of 2026, indicating strong market prospects for plozasiran.
This positive news not only enhances Arrowhead's market position but also reflects the growing confidence in its pipeline, particularly with plozasiran's promising results paving the way for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 77.950
Low
35.00
Averages
82.00
High
110.00
Current: 77.950
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the BofA Securities 2026 Healthcare Conference from May 12-14, 2026, featuring an investor group dinner and a fireside chat presentation, showcasing its latest advancements in RNA interference.
- Key Presentations: At the TIDES USA conference, Arrowhead will present its systemic RNAi targeting MAPT on May 13 at 4:45 PM, highlighting its potential applications in the central nervous system, which is expected to attract investor interest.
- Clinical Research Showcase: During the European Atherosclerosis Society Congress, Arrowhead will discuss the pharmacokinetics and pharmacodynamics of Plozasiran in subjects with renal or hepatic impairment, underscoring its significance in treating complex diseases.
- Strategic Commitment: Arrowhead's participation not only demonstrates its influence in the global healthcare sector but also indicates its dedication to addressing unmet medical needs through innovative drug development, further solidifying its market position.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
REDEMPLO Approved in Australia for FCS Treatment
- First Approved Drug: REDEMPLO is the first medicine approved in Australia for the treatment of familial chylomicronemia syndrome (FCS), authorized for both genetically confirmed and clinically diagnosed adult patients, marking a significant breakthrough in this therapeutic area.
- Clinical Trial Results: In the Phase 3 PALISADE study, REDEMPLO achieved an 80% median reduction in triglycerides and significantly lowered the incidence of acute pancreatitis, demonstrating its potential to improve patients' quality of life.
- Global Expansion Strategy: This approval follows those in the U.S., Canada, and China, indicating Arrowhead Pharmaceuticals' commitment to expanding global treatment options for FCS patients and enhancing its market competitiveness.
- Innovative Treatment Method: REDEMPLO is administered via self-injection every three months, providing a convenient treatment option that is expected to significantly improve long-term health management and quality of life for FCS patients.
See More
Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
- EMA Recommendation: Arrowhead Pharmaceuticals' Redemplo received a positive opinion from the European Medicines Agency (EMA) Committee, recommending approval for familial chylomicronemia syndrome, with a final decision from the European Commission expected by Q2 2026, potentially opening new market opportunities for the company.
- Wall Street Optimism: Morgan Stanley upgraded Arrowhead from ‘Equal Weight’ to ‘Overweight’ with a price target increase from $78 to $100, reflecting optimism ahead of late-stage Severe Hypertriglyceridemia (sHTG) data, which is expected to unlock a multibillion-dollar market opportunity.
- Analyst Support: According to Koyfin, 10 out of 12 analysts rated Arrowhead as ‘Buy’ or higher, indicating strong market confidence in its future performance, with an average price target of $84.18, representing a potential upside of 14%.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around ARWR stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, reflecting investor optimism for the impending drug approval in Europe, with the stock rallying approximately 454% over the past 12 months.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the BofA Securities 2026 Healthcare Conference from May 12-14, 2026, featuring an investor group dinner and a fireside chat presentation, showcasing its latest advancements in RNA interference.
- Key Presentations: At the TIDES USA conference, Arrowhead will present its systemic RNAi targeting MAPT on May 13 at 4:45 PM, highlighting its potential applications in the central nervous system, which is expected to attract investor interest.
- Clinical Research Showcase: During the European Atherosclerosis Society Congress, Arrowhead will discuss the pharmacokinetics and pharmacodynamics of Plozasiran in subjects with renal or hepatic impairment, underscoring its significance in treating complex diseases.
- Strategic Commitment: Arrowhead's participation not only demonstrates its influence in the global healthcare sector but also indicates its dedication to addressing unmet medical needs through innovative drug development, further solidifying its market position.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
REDEMPLO Approved in Australia for FCS Treatment
- First Approved Drug: REDEMPLO is the first medicine approved in Australia for the treatment of familial chylomicronemia syndrome (FCS), authorized for both genetically confirmed and clinically diagnosed adult patients, marking a significant breakthrough in this therapeutic area.
- Clinical Trial Results: In the Phase 3 PALISADE study, REDEMPLO achieved an 80% median reduction in triglycerides and significantly lowered the incidence of acute pancreatitis, demonstrating its potential to improve patients' quality of life.
- Global Expansion Strategy: This approval follows those in the U.S., Canada, and China, indicating Arrowhead Pharmaceuticals' commitment to expanding global treatment options for FCS patients and enhancing its market competitiveness.
- Innovative Treatment Method: REDEMPLO is administered via self-injection every three months, providing a convenient treatment option that is expected to significantly improve long-term health management and quality of life for FCS patients.
See More
Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
- EMA Recommendation: Arrowhead Pharmaceuticals' Redemplo received a positive opinion from the European Medicines Agency (EMA) Committee, recommending approval for familial chylomicronemia syndrome, with a final decision from the European Commission expected by Q2 2026, potentially opening new market opportunities for the company.
- Wall Street Optimism: Morgan Stanley upgraded Arrowhead from ‘Equal Weight’ to ‘Overweight’ with a price target increase from $78 to $100, reflecting optimism ahead of late-stage Severe Hypertriglyceridemia (sHTG) data, which is expected to unlock a multibillion-dollar market opportunity.
- Analyst Support: According to Koyfin, 10 out of 12 analysts rated Arrowhead as ‘Buy’ or higher, indicating strong market confidence in its future performance, with an average price target of $84.18, representing a potential upside of 14%.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around ARWR stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, reflecting investor optimism for the impending drug approval in Europe, with the stock rallying approximately 454% over the past 12 months.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
